default author photo

Patrick M. Boland

Roswell Park Comprehensive Cancer Center

Elm & Carlton Streets

Buffalo, NY 14263

United States

SCHOLARLY PAPERS

1

DOWNLOADS

138

TOTAL CITATIONS

3

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Regorafenib Dose-Optimization Study (ReDOS): A Phase 2 Randomized Study to Evaluate Dosing Strategies for Regorafenib in Patients with Refractory Metastatic Colorectal Cancer - An ACCRU Network Study

Number of pages: 28 Posted: 28 Jan 2019
Tanios Bekaii-Saab, Fang-Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis J. Dockter, Nisha L. Jacobs, Boris C. Pasche, Boris C. Pasche, James M. Cleary, Jeffrey P. Meyers, Jeannine S. McCune, Katrina Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Jeffrey Sloan, Mario E. Lacouture, Heinz-Josef Lenz and Axel Grothey
Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, Mayo Clinic, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, Roswell Park Comprehensive Cancer Center, Vanderbilt University - Department of Medicine, Mayo Clinic, Mayo Clinic, Minnesota Oncology, Wake Forest University - Comprehensive Cancer CenterWake Forest University - Department of Cancer Biology, Harvard University - Dana-Farber Cancer Institute, Mayo Clinic, University of Washington, Washington University in St. Louis - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, University of Washington - School of Medicine, Mayo Clinic, Memorial Sloan Kettering Cancer Center - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center and West Cancer Center and Research Institute
Downloads 138 (530,816)
Citation 3

Abstract:

Loading...

Refractory metastatic colorectal cancer, Regorafenib, Dose-optimization, Phase 2, Dosing strategies